SAB Biotherapeutics Warrant
SABSW
7 hedge funds and large institutions have $8.34K invested in SAB Biotherapeutics Warrant in 2025 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 4 closing their positions.
30% less funds holding
Funds holding: 10 → 7 (-3)
57% less capital invested
Capital invested by funds: $19.5K → $8.34K (-$11.2K)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GS
GTS Securities
New York
|
+$1.25K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LP
LMR Partners
London,
United Kingdom
|
-$12.6K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$750 |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$524 |
| 4 |
Walleye Trading
New York
|
-$268 |
| 5 |
CS
Clear Street
New York
|
-$6 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Morgan Stanley
New York
| $4.57K | – | – | – |
|
|
CS
2
Clear Street
New York
| $2.46K | -$6 | -200 | -0.3% |
|
|
GS
3
GTS Securities
New York
| $1.03K | +$1.25K | +41,101 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $192 | -$524 | -17,228 | -74% |
|
|
WAM
5
Wolverine Asset Management
Chicago,
Illinois
| $57 | – | – | – |
|
|
NA
6
NewEdge Advisors
New Orleans,
Louisiana
| $33 | – | – | – |
|
7
Bank of America
Charlotte,
North Carolina
| $3 | -$3 | -100 | -50% |
|
|
LP
8
LMR Partners
London,
United Kingdom
| – | -$12.6K | -539,588 | Closed |
|
|
9
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$750 | -26,302 | Closed |
|
|
10
Walleye Trading
New York
| – | -$268 | -11,436 | Closed |
|
11
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$5 | -200 | Closed |
|
SABSW Hedge Fund Activity: Q4 2025 in Review
7 of the 8,238 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics Warrant (SABSW) for Q4 2025, worth a combined $8.34K — down 57% from $19.5K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of SABSW and 1 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 0 added.
The largest buyer was GTS Securities, opening a new position worth an estimated $1.25K. The largest seller was LMR Partners, exiting entirely with an estimated $12.6K sold.
- 7 institutional investors held SAB Biotherapeutics Warrant (SABSW) as of Q4 2025, down from 10 in Q3 2025.
- Funds reported $8.34K of SAB Biotherapeutics Warrant stock for Q4 2025, down 57% quarter-over-quarter.
- 1 fund opened new SAB Biotherapeutics Warrant positions in Q4 2025 and 4 closed out, a net change of -3 holders.
- The largest SAB Biotherapeutics Warrant buyer in Q4 2025 was GTS Securities, an estimated $1.25K added.
- The largest SAB Biotherapeutics Warrant seller in Q4 2025 was LMR Partners, an estimated $12.6K sold.
Based on aggregated 13F filings for Q4 2025.